Automated manufacturing of clinical-grade BDCA2 CAR NK cells in a closed system for the treatment of blastic plasmacytoid dendritic cell neoplasm

Recent progress in chimeric antigen receptor (CAR) natural killer (NK) cell therapy has demonstrated their promising potential in cancer immunotherapy. However, most current CAR NK cell manufacturing processes utilize open systems with multiple manual steps, making it challenging to maintain consist...

Descripció completa

Dades bibliogràfiques

Autors principals:	Rita Pfeifer, Sabine Müller, Marcus Nitsche, Melanie Sohmen, Julia Kostyra, Arthur Bister, Cathrin Bleilevens, Janina Brauner, Angela Mekes, Juliane Raasch, Dominika Lukas, Jens Kopatz, Wael Al Rawashdeh, Marsilius Mues, José Alberto Villacorta Hidalgo, Volker Huppert, Mario Assenmacher, Nina Möker, Rimas Orentas, Congcong Zhang
Format:	Artigo
Idioma:	Inglês
Publicat:	Frontiers Media S.A. 2026-02-01
Col·lecció:	Frontiers in Immunology
Matèries:	automated manufacturing BDCA2 CAR BPDCN cancer immunotherapy CAR NK cells CliniMACS Prodigy NKCT
Accés en línia:	https://www.frontiersin.org/articles/10.3389/fimmu.2026.1761397/full
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!